| ID | Analyse ▼ | Domein | Recipiënt | Uitvoering | LTAT (uren (dagen)) | Accred. | LOINCeenheid (1) | LOINCeenheid (2) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 8522 | Appaloosa patroon 1 | EDTA |
– | – | – | › | ||||
| 22285 | Apolipoproteine B Apo B | Serum |
maandag t/m vrijdag | 25 (1) | – | 1884-6 g/L | – | › | ||
| 22283 | Apolipoproteine A1 Apo A1 | Serum |
maandag t/m vrijdag | 23 (1) | – | 1869-7 g/L | – | › | ||
| 21339 | APC resistentie APC resistentie | Citraat |
2× per week, voorzien op dinsdag en vrijdag | 95 (4) | – | 48591-2 | – | › | ||
| 21310 | Antitrombine ATIII | Citraat |
2× per week, voorzien op dinsdag en vrijdag | 90 (3,8) | – | 27811-9 % | – | › | ||
| 1313 | Antithrombine (dier) | Citraat |
maandag t/m vrijdag | 67 (2,8) | – | – % | – | › | ||
| 23236 | Antineutr.cytopl.As(ANCA) ANCA, Anti-cytoplasmatische antistoffen | Serum |
maandag t/m vrijdag | 76 (3,2) | – | 35279-9 | – | › | ||
| 56205 | Antimoon (volbloed) Sb | Oligo-elementen (spoorelementen) |
tenminste 2× per week | – | 5578-0 µg/l | 50809-3 nmol/L | › | |||
| ● 25242 | Antidiuretisch hormoon ADH, Vasopressine | EDTA |
1× per 2 weken | 398 (16,6) | – | 3126-0 pg/ml | 3126-0 ng/l | › | ||
| 8298 | Antidepress.opsporen/id. | Urine |
381 (15,9) | – | 19312-8 | – | › | |||
| 4484 | anti Delta As Hepatitis D virus As | Serum |
312 (13) | – | 95141-8 | – | › | |||
| 1343 | anti-Xa Rivaroxaban Anti-Xa (New Oral AntiCoagulants) | Citraat |
1× per week | – | 74871-5 ng/mL | – | › | |||
| 1344 | Anti-Xa Apixaban | Citraat |
maandag t/m vrijdag | 18 (0,7) | – | 74214-8 ng/mL | – | › | ||
| 3316 | anti-VGCC (Ca kanaal As) | Serum |
412 (17,2) | – | 31024-3 pmol/L | – | › | |||
| 24017 | Anti-transglutaminase IgG anti-transglutaminase IgG, Tissue Transglutaminase IgG, tTG IgG | Serum |
maandag t/m vrijdag | 7 (0,3) | – | 32998-7 U/ml | 56537-4 U/ml | › | ||
| 24016 | Anti-transglutaminase IgA anti-transglutaminase IgA, Tissue Transglutaminase IgA, tTG IgA | Serum |
maandag t/m vrijdag | 10 (0,4) | – | 31017-7 U/ml | 46128-5 U/ml | › | ||
| 24952 | Anti-TPO As | Serum |
maandag t/m vrijdag | – | 8099-4 IU/mL | – | › | |||
| 24948 | Anti-thyroglobuline As Anti-TG antistoffen, Colloïd antistoffen, Thyreoglobuline antistoffen | Serum |
maandag t/m vrijdag | 5 (0,2) | B | 8098-6 IU/mL | – | › | ||
| 24185 | Anti-Tetanus Toxoid IgG | Serum |
1× per week | 177 (7,4) | – | – IU/mL | – | › | ||
| 3313 | Anti-nucleosomen | Serum |
– | 53014-7 U/ml | – | › | ||||
| 3277 | anti-MuSK As Anti-muscle specific kinase antistoffen | Serum |
278 (11,6) | – | 94273-0 | – | › | |||
| 25054 | Anti-Müllerian Hormoon | Serum |
maandag t/m vrijdag | 23 (1) | B | 38476-8 ng/mL | – | › | ||
| 23355 | Anti-MOG titer | Lumbaalvocht (CSV) |
– | – | – | › | ||||
| 23353 | Anti-MOG titer | Serum |
149 (6,2) | – | 84873-9 | – | › | |||
| 23304 | Anti-MOG (1/10) Myeline oligodentrocyte glycoproteïne antistoffen (1/10) | Serum |
1× per 1–2 weken | 46 (1,9) | – | 106548-1 | – | › | ||
| 23354 | Anti-MOG (1/1) Myeline oligodentrocyte glycoproteïne antistoffen (1/1) | Lumbaalvocht (CSV) |
1× per 1–2 weken | 112 (4,7) | – | 91543-9 | – | › | ||
| 24611 | Anti-Mazelen IgG | Serum |
3× per week | 58 (2,4) | B | 7962-4 IU/L | 7962-4 mIU/mL | › | ||
| 3242 | anti-MAG As Myeline geassocieerde glycoproteïne antistoffen | Serum |
873 (36,4) | – | 31023-5 | – | › | |||
| 23206 | Anti-intrinsic factor IgG Anti-intrisic factor antistoffen, Intrisic factor antistoffen | Serum |
maandag t/m vrijdag | 34 (1,4) | – | 56539-0 U/mL | – | › | ||
| 2592 | anti-IA2 antilichamen | Serum |
1× per maand | 909 (37,9) | – | 31209-0 U/mL | – | › | ||
| 3314 | Anti-histonen | Serum |
– | 17380-7 U/ml | – | › | ||||
| 24497 | anti-HBs voor booster HBV surface antistoffen voor booster | Serum |
1 (0,1) | B | – mIU/mL | – | › | |||
| 24506 | anti-HBs na booster 5 | Serum |
1 (0) | – | – mIU/mL | – | › | |||
| 24499 | anti-HBs na booster HBV surface antistoffen na booster | Serum |
1 (0,1) | B | – mIU/mL | – | › | |||
| 24496 | anti-HBs na 4 weken HBV surface antistoffen na 4 weken | Serum |
maandag t/m vrijdag | 1 (0) | B | – mIU/mL | – | › | ||
| 3306 | anti-glycine receptor As | Serum |
319 (13,3) | – | 95722-5 | – | › | |||
| 24002 | Anti-gliadine DP IgG Gedeamideerde gliadine IgG | Serum |
maandag t/m vrijdag | 7 (0,3) | – | 58710-5 U/ml | 20496-6 U/ml | › | ||
| 24000 | Anti-gliadine DP IgA Gedeamideerde gliadine IgA | Serum |
maandag t/m vrijdag | 10 (0,4) | – | 63453-5 U/ml | – | › | ||
| 3258 | anti-ganglioside AS | Serum |
667 (27,8) | – | 82455-7 | – | › | |||
| 22591 | anti-GAD Anti Glutamic Acid Decarboxylase 65 antistoffen, GAD65 antistoffen, GADA | Serum |
1× per 1–2 weken | 175 (7,3) | – | 56540-8 IU/mL | – | › | ||
| 1342 | anti-factor Xa | Citraat |
1× per week | 96 (4) | – | 3216-9 IU/ml | – | › | ||
| 24021 | Anti-Endomysium IgG 1/10 | Serum |
tenminste 1× per week | 26 (1,1) | – | 39554-1 | – | › | ||
| 24006 | Anti-Endomysium IgA 1/10 | Serum |
tenminste 1× per week | 156 (6,5) | – | 46126-9 | – | › | ||
| 23138 | Anti-CCP Anti-Cyclic Citrullinated Peptide, Cyclic Citrullinated Peptide Antibody, Cyclisch gecitrullineerde peptiden | Serum |
maandag t/m vrijdag | 3 (0,1) | – | 53027-9 U/ml | – | › | ||
| 23307 | Anti-cardiolipine IgM Anti-fosfolipiden antistoffen, Cardiolipine IgM | Serum |
maandag t/m vrijdag | 26 (1,1) | – | 3182-3 MPL U/ml | – | › | ||
| 23308 | Anti-cardiolipine IgG Anti-fosfolipiden antistoffen, Cardiolipine IgG | Serum |
maandag t/m vrijdag | 26 (1,1) | – | 3181-5 GPL U/ml | – | › | ||
| 23338 | Anti-Aquaporine-4 titer | Lumbaalvocht (CSV) |
– | – | – | › | ||||
| 23336 | Anti-Aquaporine-4 titer | Serum |
99 (4,1) | – | 95273-9 | – | › | |||
| 23282 | Anti-Aquaporine-4 (1/10) Anti-NMO (1/10) | Serum |
1× per 1–2 weken | 46 (1,9) | – | 43638-6 | – | › | ||
| 23337 | Anti-Aquaporine-4 (1/1) Anti-NMO (1/1) | Lumbaalvocht (CSV) |
1× per 1–2 weken | 129 (5,4) | – | – | – | › |
